protein scaffolds, vaccines, immunotherapies, enzymes and also very hydrophobic small molecules. The company focuses the development of its own products on treatment of chronic diseases, such as diabetes and inflammatory diseases. In addition to that, a particular area of interest is oral immunotherapy, as our technology has shown an outstanding performance in this area.

BioLingus’ main office is in Switzerland, and we have a satellite company in Hong Kong.